"This will hasten the development of the COVID-19 vaccine", the Health Ministry said in a statement.
Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding of the needed immune response into cells.
The SII received approval by India's top drug regulator on Sunday after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.
"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals", the official said. The report highlighted that the firm conducting clinical trials of potential Coronavirus vaccine in India will have to submit the safety data to the CDSCO which will be first evaluated by the Data Safety Monitoring Board (DSMB), before Phase III clinical trials are initiated. Around 1,600 people above 18 years of age will participate in the trials across 17 selected sites.
Health authorities are planning to roll out a mass vaccination campaign in October, he said.
His company, which has teamed up with the Oxford scientists developing the vaccine, was one of the first to boldly announce, in April, that it was going to mass-produce a vaccine before clinical trials even ended.
As the world is battling against the surge in coronavirus cases, Russian Federation has announced that it plans to register its COVID-19 vaccine by 12th August.
But right now it's not entirely clear how much of the coronavirus vaccine that Serum will mass-produce will be kept by India or who will fund its production, leaving the Poonawallas to navigate a torrent of cross-pressures, political, financial, external and domestic.
"We will be able to ensure production volumes of several hundred thousand a month, with an eventual increase to several million by the start of next year", he said, adding that one developer is preparing production technology at three locations in central Russian Federation. "It is envisaged that, once a vaccine has proven to be safe and effective against COVID-19, the Commission would have a contractual framework in place for the purchase of 300 million doses, on behalf of all European Union member states", it said in a statement.